title: Building better biotherapeutics and vaccines by design: EpiVax, Inc., an immunology company.
abstract: EpiVax, Inc., is an early-stage informatics and immunology biotechnology company in Providence, Rhode Island. It applies computational tools to harness immunity in three major areas: immunomodulation, biotherapeutic immunogenicity risk assessment and de-risking, and vaccine development. Immunotherapy, bio-better and vaccine candidates under development at EpiVax promise to improve the health outcomes of millions of people affected by devastating immune-related diseases.
authors: Senior director vaccine research at EpiVax.
authors: Leonard
authors: L
authors: Moise
authors: Annie
authors: A
authors: De Groot
authors: Anthony
authors: A
authors: Marcello
authors: Ryan
authors: R
authors: Tassone
authors: William
authors: W
authors: Martin
authors: Leslie
authors: L
authors: Cousens
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D015551:Autoimmunity; D035843:Biomedical Research / Q000639:trends*; D019295:Computational Biology; D015195:Drug Design; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry; D006801:Humans; D016056:Immunodominant Epitopes / Q000276:immunology*; D056747:Immunomodulation; D012237:Rhode Island; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014612:Vaccines
chemical_list: D016056:Immunodominant Epitopes; D014612:Vaccines
keywords: autoimmune diseases; immuno- therapy; immunoinformatics; immunomodulation; vaccines